Telix Pharmaceuticals Limited: Prostatic Neoplasms trials

The registry lists 10 Prostatic Neoplasms studies with Telix Pharmaceuticals Limited as lead sponsor. 2 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 1Phase 2 1Phase 3 4No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)RecruitingNCT06520345Phase 3
• 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese PatientsRecruitingNCT05847348Phase 3
• PSMA PET Combined With MRI for the Detection of PCaActive, not recruitingNCT07052214Phase 3
• Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging EvaluationsTerminatedNCT06655064
• External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)CompletedNCT05146973Phase 2
• The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care OnlyTerminatedNCT04876651Phase 3
• 177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry StudyCompletedNCT04786847Phase 1
• 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)CompletedNCT04726033Early Phase 1
• Evaluation of the SENSEI® Laparoscopic Tethered Gamma Probe for 99mTc-nanocolloid Sentinel Lymph Node Biopsy in Prostate CancerStatus unknownNCT04632251Not applicable
• PRIME - PRostate Imaging for Margin EvaluationCompletedNCT02151097